PTC Therapeutics, Inc. (PTCT)
After hours:
| Previous close | 25.41 |
| Open | 25.79 |
| Bid | 25.16 x 300 |
| Ask | 25.24 x 300 |
| Day's range | 24.85 - 25.99 |
| 52-week range | 17.53 - 59.84 |
| Volume | |
| Avg. volume | 898,040 |
| Market cap | 1.931B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.37 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.91 |
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved non-statutory stock options to purchase an aggregate of 8,090 shares of its common stock and 8,290 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to six new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
ZacksPTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswirePTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m. ET.
